Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Class I Phosphatidylinositol 3-Kinases | 21 | 2024 | 899 | 4.670 |
Why?
|
Thiazoles | 12 | 2024 | 1517 | 2.060 |
Why?
|
Breast Neoplasms | 33 | 2024 | 20982 | 1.470 |
Why?
|
Receptors, Estrogen | 12 | 2024 | 2208 | 1.440 |
Why?
|
Cyclin-Dependent Kinase 6 | 7 | 2024 | 348 | 1.290 |
Why?
|
Cyclin-Dependent Kinase 4 | 8 | 2024 | 559 | 1.260 |
Why?
|
Protein Kinase Inhibitors | 23 | 2024 | 5665 | 1.250 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11733 | 1.130 |
Why?
|
Receptor, erbB-2 | 13 | 2024 | 2553 | 1.020 |
Why?
|
Imidazoles | 5 | 2024 | 1172 | 0.930 |
Why?
|
Pyridines | 7 | 2024 | 2872 | 0.820 |
Why?
|
Oxazepines | 3 | 2024 | 22 | 0.800 |
Why?
|
Drug Resistance, Neoplasm | 16 | 2023 | 5301 | 0.790 |
Why?
|
PTEN Phosphohydrolase | 2 | 2019 | 1111 | 0.760 |
Why?
|
Neoplasms | 21 | 2024 | 22142 | 0.740 |
Why?
|
Receptor, erbB-3 | 4 | 2018 | 142 | 0.740 |
Why?
|
Mutation | 26 | 2024 | 30004 | 0.730 |
Why?
|
Phosphatidylinositol 3-Kinases | 10 | 2024 | 2864 | 0.720 |
Why?
|
Autopsy | 4 | 2021 | 1010 | 0.670 |
Why?
|
Piperazines | 7 | 2024 | 2522 | 0.640 |
Why?
|
Organic Chemicals | 1 | 2018 | 210 | 0.570 |
Why?
|
Tumor Microenvironment | 5 | 2024 | 3875 | 0.570 |
Why?
|
Immunoconjugates | 5 | 2024 | 963 | 0.560 |
Why?
|
Proto-Oncogene Proteins c-akt | 6 | 2024 | 2455 | 0.540 |
Why?
|
Maximum Tolerated Dose | 6 | 2024 | 883 | 0.540 |
Why?
|
TOR Serine-Threonine Kinases | 7 | 2024 | 2058 | 0.540 |
Why?
|
Benzoxazoles | 1 | 2017 | 91 | 0.530 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 4 | 2024 | 212 | 0.530 |
Why?
|
Bile Duct Neoplasms | 4 | 2024 | 607 | 0.520 |
Why?
|
Hyperglycemia | 1 | 2024 | 1375 | 0.490 |
Why?
|
Cholangiocarcinoma | 4 | 2024 | 554 | 0.490 |
Why?
|
Camptothecin | 4 | 2024 | 591 | 0.480 |
Why?
|
Breast Neoplasms, Male | 3 | 2024 | 212 | 0.480 |
Why?
|
DNA Mutational Analysis | 4 | 2021 | 4107 | 0.480 |
Why?
|
Morpholines | 1 | 2017 | 581 | 0.450 |
Why?
|
Xenograft Model Antitumor Assays | 9 | 2024 | 3593 | 0.430 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2024 | 8531 | 0.420 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 5 | 2024 | 1746 | 0.390 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2018 | 10756 | 0.360 |
Why?
|
Receptors, Progesterone | 6 | 2024 | 1129 | 0.340 |
Why?
|
Mice, Nude | 6 | 2019 | 3606 | 0.340 |
Why?
|
Female | 74 | 2024 | 392552 | 0.330 |
Why?
|
Pyrimidinones | 2 | 2024 | 385 | 0.310 |
Why?
|
Aged | 42 | 2024 | 169292 | 0.290 |
Why?
|
Head and Neck Neoplasms | 3 | 2017 | 2894 | 0.280 |
Why?
|
Genital Neoplasms, Female | 1 | 2012 | 533 | 0.270 |
Why?
|
Humans | 95 | 2024 | 761222 | 0.270 |
Why?
|
Middle Aged | 44 | 2024 | 220858 | 0.260 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2017 | 4021 | 0.260 |
Why?
|
Antineoplastic Agents | 11 | 2024 | 13632 | 0.250 |
Why?
|
Cell Line, Tumor | 21 | 2024 | 16954 | 0.250 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2019 | 651 | 0.250 |
Why?
|
Gene Expression Profiling | 9 | 2024 | 9417 | 0.240 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2007 | 430 | 0.240 |
Why?
|
Gene Dosage | 4 | 2007 | 1217 | 0.240 |
Why?
|
Single-Cell Analysis | 5 | 2024 | 2452 | 0.240 |
Why?
|
Adult | 39 | 2024 | 221120 | 0.230 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2024 | 70 | 0.230 |
Why?
|
Immunoglobulin G | 2 | 2015 | 4537 | 0.230 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2024 | 628 | 0.220 |
Why?
|
Aged, 80 and over | 18 | 2024 | 58952 | 0.220 |
Why?
|
Pyrimidines | 6 | 2024 | 3027 | 0.210 |
Why?
|
Molecular Biology | 1 | 2007 | 573 | 0.210 |
Why?
|
Tumor Cells, Cultured | 3 | 2019 | 6125 | 0.210 |
Why?
|
bcl-X Protein | 1 | 2024 | 410 | 0.200 |
Why?
|
Administration, Oral | 3 | 2022 | 4015 | 0.200 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2024 | 326 | 0.200 |
Why?
|
Glutathione Transferase | 1 | 2024 | 564 | 0.200 |
Why?
|
Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2022 | 30 | 0.200 |
Why?
|
Blood | 1 | 2024 | 596 | 0.200 |
Why?
|
BRCA1 Protein | 2 | 2020 | 1149 | 0.200 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2021 | 103 | 0.190 |
Why?
|
Acetonitriles | 1 | 2021 | 54 | 0.190 |
Why?
|
Meningeal Carcinomatosis | 1 | 2021 | 63 | 0.190 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5321 | 0.190 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2019 | 256 | 0.180 |
Why?
|
Aortic Aneurysm | 2 | 2022 | 648 | 0.180 |
Why?
|
Acidosis, Lactic | 1 | 2022 | 146 | 0.180 |
Why?
|
Receptors, Interleukin-1 | 1 | 2001 | 262 | 0.180 |
Why?
|
Biliary Tract Neoplasms | 1 | 2022 | 185 | 0.180 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2005 | 492 | 0.180 |
Why?
|
Genetic Heterogeneity | 2 | 2021 | 734 | 0.180 |
Why?
|
Nerve Growth Factor | 1 | 2001 | 157 | 0.180 |
Why?
|
Neoplasm Metastasis | 8 | 2024 | 4909 | 0.180 |
Why?
|
Phenylurea Compounds | 3 | 2019 | 529 | 0.170 |
Why?
|
Brain Neoplasms | 5 | 2021 | 9025 | 0.170 |
Why?
|
Myocardium | 2 | 2024 | 4746 | 0.170 |
Why?
|
Glycolysis | 1 | 2024 | 836 | 0.170 |
Why?
|
Immunotherapy | 4 | 2023 | 4642 | 0.170 |
Why?
|
Purines | 2 | 2021 | 609 | 0.170 |
Why?
|
Trabecular Meshwork | 1 | 2020 | 101 | 0.170 |
Why?
|
Aqueous Humor | 1 | 2020 | 153 | 0.170 |
Why?
|
Fovea Centralis | 1 | 2020 | 126 | 0.170 |
Why?
|
Immune Evasion | 1 | 2023 | 364 | 0.160 |
Why?
|
Aminopyridines | 2 | 2021 | 573 | 0.160 |
Why?
|
Semaphorins | 1 | 2019 | 96 | 0.160 |
Why?
|
Estrogen Receptor alpha | 2 | 2023 | 582 | 0.160 |
Why?
|
NF-kappa B | 2 | 2024 | 2475 | 0.160 |
Why?
|
Fever | 2 | 2024 | 1618 | 0.160 |
Why?
|
Aorta, Thoracic | 2 | 2023 | 1096 | 0.160 |
Why?
|
Rats, Nude | 1 | 2018 | 106 | 0.160 |
Why?
|
Aniline Compounds | 1 | 2024 | 1073 | 0.160 |
Why?
|
Genome | 1 | 2007 | 1738 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 809 | 0.160 |
Why?
|
DNA, Neoplasm | 2 | 2019 | 1743 | 0.160 |
Why?
|
Glutathione Peroxidase | 1 | 2019 | 258 | 0.150 |
Why?
|
Colitis | 2 | 2024 | 1234 | 0.150 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2016 | 1625 | 0.150 |
Why?
|
Interleukin-1 | 1 | 2001 | 1250 | 0.150 |
Why?
|
Mice | 14 | 2024 | 81330 | 0.150 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2007 | 1549 | 0.150 |
Why?
|
DNA Barcoding, Taxonomic | 1 | 2018 | 132 | 0.140 |
Why?
|
Signal Transduction | 9 | 2024 | 23419 | 0.140 |
Why?
|
Cell Proliferation | 5 | 2019 | 10423 | 0.140 |
Why?
|
Male | 33 | 2024 | 360703 | 0.140 |
Why?
|
Aortic Diseases | 1 | 2023 | 735 | 0.140 |
Why?
|
Interferons | 1 | 2020 | 702 | 0.140 |
Why?
|
Myocarditis | 1 | 2024 | 792 | 0.140 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2019 | 349 | 0.140 |
Why?
|
Radiation Tolerance | 1 | 2019 | 478 | 0.130 |
Why?
|
Genes, MDR | 2 | 2006 | 36 | 0.130 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2020 | 943 | 0.130 |
Why?
|
Eye | 1 | 2020 | 713 | 0.130 |
Why?
|
Esophageal Neoplasms | 2 | 2017 | 1658 | 0.130 |
Why?
|
Sulfonamides | 2 | 2024 | 1977 | 0.130 |
Why?
|
Quinolines | 2 | 2019 | 764 | 0.130 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2022 | 695 | 0.130 |
Why?
|
Point Mutation | 1 | 2021 | 1593 | 0.130 |
Why?
|
Cell Adhesion Molecules | 4 | 2024 | 1603 | 0.130 |
Why?
|
Pancreatic Neoplasms | 2 | 2024 | 5366 | 0.130 |
Why?
|
BRCA2 Protein | 1 | 2020 | 797 | 0.120 |
Why?
|
Apoptosis | 3 | 2019 | 9478 | 0.120 |
Why?
|
Oligopeptides | 1 | 2020 | 1179 | 0.120 |
Why?
|
Treatment Outcome | 15 | 2024 | 64681 | 0.110 |
Why?
|
Animals | 16 | 2024 | 168089 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2019 | 987 | 0.110 |
Why?
|
Intraocular Pressure | 1 | 2020 | 1294 | 0.110 |
Why?
|
Antigens, Neoplasm | 4 | 2024 | 1985 | 0.110 |
Why?
|
Reference Values | 1 | 2021 | 4921 | 0.110 |
Why?
|
Astrocytes | 1 | 2001 | 1341 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 731 | 0.110 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2016 | 655 | 0.110 |
Why?
|
Oxazoles | 2 | 2024 | 199 | 0.110 |
Why?
|
Intestinal Mucosa | 1 | 2024 | 3031 | 0.110 |
Why?
|
Adenosine Triphosphate | 1 | 2019 | 1988 | 0.100 |
Why?
|
Oligonucleotide Array Sequence Analysis | 5 | 2007 | 3777 | 0.100 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2013 | 242 | 0.100 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2813 | 0.100 |
Why?
|
Meningeal Neoplasms | 1 | 2021 | 1246 | 0.100 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 2024 | 0.100 |
Why?
|
Loss of Heterozygosity | 1 | 2014 | 662 | 0.100 |
Why?
|
Carcinoma, Ductal | 1 | 2012 | 97 | 0.100 |
Why?
|
Lymphedema | 1 | 2019 | 523 | 0.100 |
Why?
|
Lung | 2 | 2021 | 9979 | 0.100 |
Why?
|
Glucose | 1 | 2024 | 4342 | 0.100 |
Why?
|
Protein Array Analysis | 1 | 2014 | 399 | 0.100 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2019 | 955 | 0.100 |
Why?
|
Gene Amplification | 3 | 2019 | 1084 | 0.100 |
Why?
|
Prognosis | 4 | 2023 | 29688 | 0.100 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 1225 | 0.090 |
Why?
|
Glaucoma | 1 | 2020 | 1186 | 0.090 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2013 | 570 | 0.080 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2827 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4851 | 0.080 |
Why?
|
Phthalazines | 2 | 2024 | 383 | 0.080 |
Why?
|
Time Factors | 3 | 2021 | 39957 | 0.080 |
Why?
|
Kidney | 2 | 2023 | 7033 | 0.080 |
Why?
|
Atlases as Topic | 2 | 2021 | 247 | 0.080 |
Why?
|
Indoles | 1 | 2017 | 1830 | 0.080 |
Why?
|
Retina | 1 | 2020 | 2656 | 0.080 |
Why?
|
Molecular Imaging | 1 | 2016 | 818 | 0.080 |
Why?
|
Antigens, CD | 1 | 2019 | 4009 | 0.080 |
Why?
|
Salivary Gland Neoplasms | 1 | 2012 | 304 | 0.080 |
Why?
|
Chromosome Aberrations | 2 | 2005 | 1767 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2023 | 3163 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14675 | 0.080 |
Why?
|
Neoplasm Proteins | 2 | 2014 | 3594 | 0.070 |
Why?
|
Macaca fascicularis | 2 | 2020 | 901 | 0.070 |
Why?
|
Neuropeptides | 1 | 2013 | 944 | 0.070 |
Why?
|
Cohort Studies | 5 | 2021 | 41496 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2022 | 13386 | 0.070 |
Why?
|
Alleles | 2 | 2018 | 6857 | 0.070 |
Why?
|
Neoplasm Staging | 3 | 2017 | 11119 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2007 | 4567 | 0.070 |
Why?
|
Stomach Neoplasms | 1 | 2017 | 1457 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2023 | 4251 | 0.070 |
Why?
|
Multiprotein Complexes | 1 | 2013 | 1112 | 0.070 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2021 | 858 | 0.070 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 1480 | 0.070 |
Why?
|
Telemedicine | 1 | 2023 | 3051 | 0.070 |
Why?
|
Disease Progression | 2 | 2023 | 13511 | 0.060 |
Why?
|
Species Specificity | 2 | 2020 | 2406 | 0.060 |
Why?
|
Epithelial Cells | 3 | 2024 | 3671 | 0.060 |
Why?
|
Cell Survival | 3 | 2024 | 5778 | 0.060 |
Why?
|
Cerebral Cortex | 1 | 2001 | 5775 | 0.060 |
Why?
|
Liver | 1 | 2021 | 7512 | 0.060 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2006 | 310 | 0.060 |
Why?
|
Nucleic Acid Hybridization | 1 | 2007 | 1301 | 0.060 |
Why?
|
Quality of Life | 2 | 2024 | 13367 | 0.060 |
Why?
|
Aorta | 2 | 2023 | 2040 | 0.060 |
Why?
|
Aromatase Inhibitors | 2 | 2021 | 513 | 0.060 |
Why?
|
Ventricular Myosins | 1 | 2024 | 65 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2021 | 8998 | 0.060 |
Why?
|
Ubiquitin-Conjugating Enzymes | 1 | 2005 | 199 | 0.060 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2022 | 2054 | 0.060 |
Why?
|
Drug Resistance, Multiple | 1 | 2005 | 255 | 0.060 |
Why?
|
Genes, myc | 1 | 2005 | 390 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5694 | 0.060 |
Why?
|
Interferon-gamma | 2 | 2023 | 3155 | 0.060 |
Why?
|
Immunohistochemistry | 3 | 2023 | 11067 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 108 | 0.060 |
Why?
|
F-Box Proteins | 1 | 2005 | 200 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2014 | 3702 | 0.060 |
Why?
|
Chromosomes, Human | 1 | 2005 | 442 | 0.060 |
Why?
|
DNA, Complementary | 1 | 2007 | 1989 | 0.050 |
Why?
|
Drug Synergism | 2 | 2019 | 1756 | 0.050 |
Why?
|
Neuregulin-1 | 2 | 2014 | 135 | 0.050 |
Why?
|
Tumor Necrosis Factors | 1 | 2023 | 109 | 0.050 |
Why?
|
Uracil | 1 | 2024 | 207 | 0.050 |
Why?
|
RNA, Nuclear | 1 | 2022 | 29 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4513 | 0.050 |
Why?
|
Taxoids | 1 | 2006 | 668 | 0.050 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2005 | 330 | 0.050 |
Why?
|
Fibroblasts | 2 | 2024 | 4138 | 0.050 |
Why?
|
Risk Assessment | 1 | 2024 | 24022 | 0.050 |
Why?
|
Estrogen Receptor beta | 1 | 2023 | 169 | 0.050 |
Why?
|
STAT Transcription Factors | 1 | 2023 | 189 | 0.050 |
Why?
|
Mice, SCID | 2 | 2019 | 2621 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2005 | 617 | 0.050 |
Why?
|
Survival Analysis | 2 | 2021 | 10088 | 0.050 |
Why?
|
Patient Advocacy | 1 | 2024 | 358 | 0.050 |
Why?
|
Viral Load | 2 | 2021 | 3328 | 0.050 |
Why?
|
Actinin | 1 | 2022 | 163 | 0.050 |
Why?
|
Janus Kinases | 1 | 2023 | 249 | 0.050 |
Why?
|
Radioligand Assay | 1 | 2001 | 366 | 0.050 |
Why?
|
Statistics, Nonparametric | 1 | 2007 | 2854 | 0.050 |
Why?
|
Glioblastoma | 2 | 2007 | 3482 | 0.050 |
Why?
|
Spheroids, Cellular | 1 | 2023 | 329 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 152 | 0.050 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2019 | 1520 | 0.050 |
Why?
|
Subcellular Fractions | 1 | 2001 | 524 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 2915 | 0.050 |
Why?
|
GTP Phosphohydrolases | 1 | 2024 | 517 | 0.050 |
Why?
|
Stroke | 1 | 2023 | 9721 | 0.040 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2022 | 297 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18222 | 0.040 |
Why?
|
Fibronectins | 1 | 2024 | 724 | 0.040 |
Why?
|
Phosphorylation | 3 | 2018 | 8300 | 0.040 |
Why?
|
Proportional Hazards Models | 2 | 2023 | 12474 | 0.040 |
Why?
|
Autoantigens | 1 | 2024 | 888 | 0.040 |
Why?
|
Cell Cycle Proteins | 2 | 2016 | 3446 | 0.040 |
Why?
|
Glioma | 2 | 2005 | 3452 | 0.040 |
Why?
|
Surface-Active Agents | 1 | 2020 | 150 | 0.040 |
Why?
|
Paclitaxel | 2 | 2024 | 1730 | 0.040 |
Why?
|
Binding, Competitive | 1 | 2001 | 1140 | 0.040 |
Why?
|
Troponin I | 1 | 2024 | 652 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4574 | 0.040 |
Why?
|
Heart | 2 | 2024 | 4431 | 0.040 |
Why?
|
Caspases | 1 | 2023 | 878 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 228 | 0.040 |
Why?
|
Troponin T | 1 | 2024 | 780 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 6586 | 0.040 |
Why?
|
Microscopy | 1 | 2024 | 904 | 0.040 |
Why?
|
Bayes Theorem | 2 | 2017 | 2329 | 0.040 |
Why?
|
Phagocytes | 1 | 2021 | 294 | 0.040 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2024 | 736 | 0.040 |
Why?
|
Aspartic Acid Endopeptidases | 1 | 2020 | 309 | 0.040 |
Why?
|
Genome, Human | 3 | 2007 | 4423 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2022 | 3634 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2024 | 12341 | 0.040 |
Why?
|
Nausea | 1 | 2021 | 678 | 0.040 |
Why?
|
Tamoxifen | 1 | 2023 | 965 | 0.040 |
Why?
|
Pulmonary Alveoli | 1 | 2021 | 651 | 0.040 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 26072 | 0.040 |
Why?
|
Antibodies | 2 | 2018 | 2415 | 0.040 |
Why?
|
Genome-Wide Association Study | 3 | 2022 | 12676 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2015 | 9187 | 0.040 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2022 | 698 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9458 | 0.040 |
Why?
|
Iodine Radioisotopes | 1 | 2001 | 1030 | 0.040 |
Why?
|
Viral Proteins | 1 | 2005 | 1798 | 0.040 |
Why?
|
Rats, Wistar | 1 | 2001 | 1848 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 850 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2023 | 36415 | 0.040 |
Why?
|
Quinazolines | 1 | 2024 | 1371 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8002 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1783 | 0.040 |
Why?
|
Mucins | 1 | 2020 | 569 | 0.040 |
Why?
|
Transcription Factor TFIIIA | 1 | 2016 | 24 | 0.040 |
Why?
|
Indolizines | 1 | 2016 | 30 | 0.030 |
Why?
|
Thiophenes | 1 | 2021 | 569 | 0.030 |
Why?
|
Drug Interactions | 1 | 2001 | 1417 | 0.030 |
Why?
|
Cyclic N-Oxides | 1 | 2016 | 72 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2005 | 4612 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 2020 | 1900 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39127 | 0.030 |
Why?
|
Exanthema | 1 | 2021 | 503 | 0.030 |
Why?
|
Pyridinium Compounds | 1 | 2016 | 81 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2024 | 1720 | 0.030 |
Why?
|
Uterine Neoplasms | 1 | 2005 | 1420 | 0.030 |
Why?
|
Organoids | 1 | 2023 | 744 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 106 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2019 | 714 | 0.030 |
Why?
|
Organ Specificity | 1 | 2021 | 1963 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2005 | 2802 | 0.030 |
Why?
|
Blindness | 1 | 2020 | 586 | 0.030 |
Why?
|
Autophagy | 1 | 2024 | 1327 | 0.030 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2022 | 1488 | 0.030 |
Why?
|
Animals, Newborn | 1 | 2001 | 2665 | 0.030 |
Why?
|
Colon | 1 | 2024 | 1791 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2005 | 1892 | 0.030 |
Why?
|
Cell Lineage | 1 | 2024 | 2549 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2549 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 780 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2019 | 1822 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5333 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2022 | 1963 | 0.030 |
Why?
|
Immunity | 1 | 2020 | 996 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2022 | 2011 | 0.030 |
Why?
|
Sarcoma | 1 | 2005 | 1800 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1550 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2019 | 613 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2024 | 6486 | 0.030 |
Why?
|
Gene Fusion | 1 | 2016 | 355 | 0.030 |
Why?
|
Kinetics | 1 | 2001 | 6312 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10218 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2024 | 80675 | 0.030 |
Why?
|
Phosphatidylinositol Phosphates | 1 | 2014 | 201 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 3057 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2016 | 801 | 0.030 |
Why?
|
Ribosomal Protein S6 | 1 | 2013 | 71 | 0.030 |
Why?
|
Macaca mulatta | 1 | 2020 | 2328 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2024 | 2726 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2021 | 2113 | 0.030 |
Why?
|
Blood-Brain Barrier | 1 | 2019 | 1028 | 0.030 |
Why?
|
Pyrazines | 1 | 2019 | 1202 | 0.030 |
Why?
|
Binding Sites | 1 | 2001 | 5988 | 0.030 |
Why?
|
Genotype | 2 | 2021 | 12985 | 0.030 |
Why?
|
RNA, Viral | 1 | 2021 | 2839 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 464 | 0.030 |
Why?
|
Dimerization | 1 | 2014 | 887 | 0.030 |
Why?
|
Diarrhea | 1 | 2019 | 1316 | 0.030 |
Why?
|
Indazoles | 1 | 2014 | 304 | 0.020 |
Why?
|
Regeneration | 1 | 2021 | 1505 | 0.020 |
Why?
|
Cell Membrane | 1 | 2001 | 3661 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2014 | 492 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2024 | 4744 | 0.020 |
Why?
|
Epidermal Growth Factor | 1 | 2014 | 699 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2006 | 11855 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1031 | 0.020 |
Why?
|
Proteomics | 1 | 2024 | 3840 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2019 | 1605 | 0.020 |
Why?
|
Nitriles | 1 | 2016 | 971 | 0.020 |
Why?
|
Proteins | 1 | 2005 | 5993 | 0.020 |
Why?
|
Mitochondria | 1 | 2024 | 3620 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1662 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2320 | 0.020 |
Why?
|
Retinoblastoma Protein | 1 | 2014 | 671 | 0.020 |
Why?
|
Triazoles | 1 | 2016 | 902 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3608 | 0.020 |
Why?
|
Immunoblotting | 1 | 2013 | 1644 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2014 | 2263 | 0.020 |
Why?
|
Protein Kinase C | 1 | 2015 | 1202 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2024 | 3092 | 0.020 |
Why?
|
Swine | 1 | 2020 | 5909 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2016 | 2509 | 0.020 |
Why?
|
Transcriptional Activation | 2 | 2006 | 1749 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2018 | 2444 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2006 | 4872 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2014 | 1118 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2018 | 2567 | 0.020 |
Why?
|
Young Adult | 3 | 2023 | 59222 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2019 | 3114 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3552 | 0.020 |
Why?
|
Insulin | 1 | 2022 | 6588 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3412 | 0.020 |
Why?
|
DNA Repair | 1 | 2016 | 2041 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6781 | 0.020 |
Why?
|
DNA Damage | 1 | 2016 | 2443 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2013 | 1741 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2016 | 20118 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22174 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2024 | 6341 | 0.020 |
Why?
|
DNA | 2 | 2014 | 7189 | 0.020 |
Why?
|
Blotting, Western | 1 | 2014 | 5032 | 0.020 |
Why?
|
Transfection | 1 | 2014 | 5748 | 0.020 |
Why?
|
Sirolimus | 1 | 2013 | 1540 | 0.020 |
Why?
|
Algorithms | 1 | 2007 | 14025 | 0.020 |
Why?
|
Carmustine | 1 | 2005 | 137 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22128 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5755 | 0.020 |
Why?
|
RNA Interference | 1 | 2014 | 2816 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 1933 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5829 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2005 | 2871 | 0.020 |
Why?
|
Rats | 1 | 2001 | 23705 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2016 | 13402 | 0.020 |
Why?
|
Frozen Sections | 1 | 2005 | 153 | 0.010 |
Why?
|
Adolescent | 2 | 2024 | 88300 | 0.010 |
Why?
|
Paraffin Embedding | 1 | 2005 | 302 | 0.010 |
Why?
|
Dacarbazine | 1 | 2005 | 559 | 0.010 |
Why?
|
Acetylation | 1 | 2005 | 1050 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2016 | 7571 | 0.010 |
Why?
|
Computational Biology | 1 | 2013 | 3499 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10759 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 21366 | 0.010 |
Why?
|
Pregnancy | 1 | 2001 | 29893 | 0.010 |
Why?
|
Doxorubicin | 1 | 2005 | 2224 | 0.010 |
Why?
|
Phenotype | 1 | 2014 | 16575 | 0.010 |
Why?
|
Child | 1 | 2024 | 80154 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20588 | 0.010 |
Why?
|
Histones | 1 | 2005 | 2570 | 0.010 |
Why?
|
Prospective Studies | 1 | 2019 | 54437 | 0.010 |
Why?
|
Base Sequence | 1 | 2005 | 12404 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2005 | 5773 | 0.010 |
Why?
|
Chromatin | 1 | 2005 | 2946 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2005 | 17598 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2005 | 4404 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 17897 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2005 | 4935 | 0.010 |
Why?
|
United States | 1 | 2019 | 72341 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2005 | 5783 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2005 | 12747 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 9567 | 0.000 |
Why?
|